Τίτλος:
Low molecular weight heparins: the optimal treatment for venous
thromboembolism
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Venous thromboembolism (VTE) is a common vascular complication that
requires immediate as well as long-term treatment.
Unfractionated heparin (UFH), followed by oral anticoagulants (OAs), is
of proved efficacy in the treatment of deep venous thrombosis (DVT) and
pulmonary embolism (PE). However, low molecular weight heparins (LMWHs)
have successfully replaced UFH both in the prevention and in the initial
treatment of DVT and PE.
Recent trials evaluated the efficacy and safety of LMWH therapy as an
alternative to vitamin K antagonists in long-term VTE secondary
prophylaxis for all patients and in specific subgroups.
LMWHs differ considerably from each other. These agents were studied
separately, administered according to various protocols, in various
doses and for different duration of treatment. Results from prospective
randomized trials, conducted during the last decade, indicate that LMWHs
are at least as effective and yet safer than OAs in the long-term
treatment of VTE.
In this brief overview, we consider the potential advantages of
treatment with LMWH in patients with VTE.
Συγγραφείς:
Daskalopoulos, ME
Daskalopoulou, SS
Liapis, CD
Περιοδικό:
Current Medical Research and Opinion
Εκδότης:
TAYLOR & FRANCIS LTD LONDON
Λέξεις-κλειδιά:
deep venous thrombosis; low molecular weight heparin; oral
anticoagulants; tinzaparin; venous thromboembolism
DOI:
10.1185/030079904125004024
